The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Nicotinic Antagonist Augmentation of Selective Serotonin Reuptake Inhibitor-Refractory Major Depressive Disorder: A Preliminary Study
Abstract
BACKGROUND: There is evidence for nicotinic hypercholinergic mechanisms in depression. Clinical relationships between tobacco use and depression suggest important effects of nicotine in major depressive disorder (MDD). It has been hypothesized that cigarette smoking may exert antidepressant effects, presumably mediated through stimulation of nicotinic acetylcholine receptor systems. We compared the nicotinic antagonist, mecamylamine hydrochloride (MEC), with placebo as an augmentation strategy for patients with MDD who were refractory to selective serotonin reuptake inhibitor (SSRI) treatment. METHODS: Twenty-one SSRI-treated subjects with MDD were randomized to MEC (up to 10 mg/d; n = 11) or placebo (PLO group; n = 10) during an 8-week trial. The primary outcome measure was the change in depressive symptoms assessed using the 17-item Hamilton Depression Rating Scale during the 8-week trial. RESULTS: There was a significant reduction in 17-item Hamilton Depression Rating Scale scores in the MEC versus PLO groups, as evidenced by a significant medication x time interaction (F1,19 = 6.47, P < 0.05). Five (45.5%) of 11 subjects in the active study medication group demonstrated a 50% or more decrease in depressive symptoms from baseline as compared with 1 (10%) of 10 subjects assigned to placebo medication, but this difference was not significant (P = 0.15; Fisher exact test). The primary side effects of MEC were constipation and orthostatic hypotension. CONCLUSIONS: These preliminary findings suggest that the nicotinic acetylcholine receptor antagonist, MEC, may have utility as an augmentation strategy for patients with SSRI-refractory MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“is effective as an add-on medication in depressed human subjects who are nonresponsive to a selective serotonin reuptake inhibitor (SSRI) (George et al. 2008)”
From Mechanisms of Nicotine Addiction (2021) · cites this paper as George et al. 2008
In the citing paper
“clinical trials have suggested that blockade of either mAChRs (Furey and Drevets, 2006; Furey et al., 2010) or nAChRs (George et al., 2008; Shytle et al., 2002) can decrease symptoms of depression.”
From Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior (2012) · cites this paper as George et al., 2008
In the citing paper
“similar compounds have shown promising effects in smaller clinical trials, and enhanced the effects of SSRIs in human depressed subjects (George et al., 2008; Philip et al., 2009)”
From Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states (2015) · cites this paper as George et al., 2008
In the citing paper
“Recent clinical studies (Dunbar et al, 2007; George et al., 2008) have demonstrated that mecamylamine has an antidepressant-enhancing effect upon co-administration with selective serotonin reuptake inhibitors (SSRIs).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as George et al., 2008
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800
Hasin, D. S., Goodwin, R. D., Stinson, F. S., & Grant, B. F. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1097 · Cited by 1,645
A cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
Co‐Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders
Kalman, D., Morissette, S. B., & George, T. P. (2005) · The American Journal on Addictions · doi:10.1080/10550490590924728 · Cited by 594
Self-citationThe Relationship Between Antidepressant Medication Use and Rate of Suicide
Gibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.165 · Cited by 393
Nicotine addiction and comorbidity with alcohol abuse and mental illness
Dani, J. A., & Harris, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1580 · Cited by 382
Nicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279
Self-citation(1996) · PubMed · Cited by 156
Stress modulation over the day in cigarette smokers
Parrott, A. C. (2003) · Addiction · doi:10.1046/j.1360-0443.1995.9022339.x · Cited by 132
McClernon, F. J., Hiott, F. B., Westman, E. C., Rose, J. E., & Levin, E. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0516-y · Cited by 106
Stress modulation over the day in cigarette smokers
Parrott, A. C. (1995) · Addiction · doi:10.1111/j.1360-0443.1995.tb01041.x · Cited by 100
Shytle, R. D., Silver, A. A., Sheehan, K. H., Sheehan, D. V., & Sanberg, P. R. (2002) · Depression and Anxiety · doi:10.1002/da.10035 · Cited by 77
Self-citationBaker, C. B., Tweedie, R. L., Duval, S., & Woods, S. W. (2003) · Depression and Anxiety · doi:10.1002/da.10079 · Cited by 42
Shytle, R. D., Silver, A. A., & Sanberg, P. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00945-8 · Cited by 41
Self-citationHeightened Stress and Depression Follow Cigarette Smoking
Parrott, A. C. (2004) · Psychological Reports · doi:10.2466/pr0.94.1.33-34 · Cited by 39
Cited by
Sorted by citations
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Taly, A., Corringer, P., Guédin, D., Lestage, P. J., & Changeux, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2927 · Cited by 743
Nicotinic acetylcholine receptors: From basic science to therapeutics
Hurst, R. S., Rollema, H., & Bertrand, D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.012 · Cited by 543
Mineur, Y. S., Obayemi, A., Wigestrand, M. B., Fote, G. M., Calarco, C. A., Li, A. M., & Picciotto, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219731110 · Cited by 375
Metadata
- Authors
- George, T. P., Sacco, K. A., Vessicchio, J. C., Weinberger, A. H., & Shytle, R. D.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- Yale University (US)
- University of South Florida (US)
- Corresponding author
- George, Tony P.
- Sacco, Kristi A.
- Vessicchio, Jennifer C.
- Weinberger, Andrea H.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-06
- Volume
- 28
- Issue
- 3
- Pages
- 340-344
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1985905713
- Cited by
- 128
- References
- 17
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 11 · 2012: 13
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- University of South Florida
- Ministerio de Economía y Competitividad
- National Institute on Drug Abuse (5K02 DA 16611, K02DA016611)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- major depressive disorder, mecamylamine, nicotinic acetylcholine receptor antagonism, antidepressant augmentation, nicotine, depressive symptoms
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Mecamylamine, Middle Aged, Personality Inventory, Psychometrics, Selective Serotonin Reuptake Inhibitors, Nicotinic Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
